ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional

A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

ClinicalTrials.gov ID: NCT06075667

Public ClinicalTrials.gov record NCT06075667. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 20, 2026, 7:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Efficacy, Safety, and Pharmacokinetics of Tirzepatide Once Weekly Versus Placebo in Adolescent Participants Who Have Obesity, or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind Trial (SURMOUNT-ADOLESCENTS)

Study identification

NCT ID
NCT06075667
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Eli Lilly and Company
Industry
Enrollment
150 participants

Conditions and interventions

Interventions

  • Placebo Drug
  • Tirzepatide Drug

Drug

Eligibility (public fields only)

Age range
12 Years to 17 Years
Sex
All
Healthy volunteers
Not listed

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 15, 2023
Primary completion
Apr 30, 2026
Completion
Jun 30, 2029
Last update posted
Jun 24, 2025

2023 – 2029

United States locations

U.S. sites
10
U.S. states
9
U.S. cities
10
Facility City State ZIP Site status
CenExel iResearch, LLC Decatur Georgia 30030
Solaris Clinical Research Meridian Idaho 83646
Cotton O'Neil Diabetes & Endocrinology Topeka Kansas 66606
Pennington Biomedical Research Center Baton Rouge Louisiana 70808
Barry J. Reiner, MD, LLC Baltimore Maryland 21229
M Health Fairview - Delaware Clinical Research Unit (DCRU) Minneapolis Minnesota 55414
Washington University School of Medicine St Louis Missouri 63110
Aventiv Research Inc Columbus Ohio 43213
PriMED Clinical Research Dayton Ohio 45429
Vanderbilt Health One Hundred Oaks Nashville Tennessee 372212

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 23 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06075667, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 24, 2025 · Synced Apr 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06075667 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →